KMDAKamada Ltd.

$7.78+21% 1Y

$7.78

$6.4152 weeks$9.04

Is the price fair?

Mixed

In its normal P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 neutral, 2 without data

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 22.2 vs a 22.1 median over 12 quarters (+0% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Kamada Ltd. trades at 22.2× earnings against 19.6× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

22.2

Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.6 · 1.13× the median: the market pays up for this one

Details›

What the market has paid for these earnings: 12 quarters of its own multiple × $0.35 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$6.78
Its own P/E history, median	$7.74
Its own P/E history, upper quartile	$13.50
52-week range	$6.41 – $9.04
Today	$7.78

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Ranks #10 of 41 by RyuScore